In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX) reported that D E Shaw has picked up 3,707,857 of common stock as of 2017-03-06.
The acquisition brings the aggregate amount owned by D E Shaw to a total of 3,707,857 representing a 5.0% stake in the company.
For those not familiar with the company, BioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. Its drug candidates include RAPIVAB, RAPIACTA, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, BCX4430 and Forodesine. Its product RAPIVAB contains peramivir. Peramivir is an intravenous neuraminidase inhibitor approved in various countries for the treatment of patients with influenza, in the United States as RAPIVAB. RAPIVAB is used for the treatment of acute uncomplicated influenza. Its BCX4430 is a broad-spectrum antiviral (BSAV) research program.
A glance at Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX)’s key stats reveals a current market capitalization of 597.06 Million based on 73.96 Million shares outstanding and a price at last close of $7.80 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-02-05, Baker picked up 45,000 at a purchase price of $6.33. This brings their total holding to 12,894,240 as of the date of the filing.
On the sell side, the most recent transaction saw Staab unload 3,250 shares at a sale price of $7.45. This brings their total holding to 124,187.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.